Skip to main content

CRISPR Therapeutics AG

For the period ended Dec 31, 2024. Filed Feb 11, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 11, 2025

CRSP$50.04-0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

CRISPR Therapeutics AG
Date: February 11, 2025By:/s/ Samarth Kulkarni
Samarth Kulkarni
Chief Executive Officer

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned directors and officers of CRISPR Therapeutics AG (the “Company”), hereby severally constitute and appoint Samarth Kulkarni, Raju Prasad and James R. Kasinger, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of us might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Samarth KulkarniChief Executive Officer, Chairman and DirectorFebruary 11, 2025
Samarth Kulkarni(Principal Executive Officer)
/s/ Raju PrasadChief Financial OfficerFebruary 11, 2025
Raju Prasad(Principal Financial and Accounting Officer)
/s/ Ali BehbahaniDirectorFebruary 11, 2025
Ali Behbahani
/s/ Maria FardisDirectorFebruary 11, 2025
Maria Fardis
/s/ H. Edward Fleming, Jr.DirectorFebruary 11, 2025
H. Edward Fleming, Jr.
/s/ Simeon J. GeorgeDirectorFebruary 11, 2025
Simeon J. George
/s/ John GreeneDirectorFebruary 11, 2025
John Greene
/s/ Katherine A. HighDirectorFebruary 11, 2025
Katherine A. High
/s/ Sandesh MahatmeDirectorFebruary 11, 2025
Sandesh Mahatme
/s/ Christian RommelDirectorFebruary 11, 2025
Christian Rommel
/s/ Douglas A. TrecoDirectorFebruary 11, 2025
Douglas A. Treco
/s/ Raju PrasadAuthorized Representative in the United StatesFebruary 11, 2025
Raju Prasad
Index to Consolidated Financial StatementsPages
Report of Independent Registered Public Accounting Firm (PCAOB ID No. 42)F-1
Consolidated Balance SheetsF-3
Consolidated Statements of Operations and Comprehensive LossF-4
Consolidated Statements of Shareholders' EquityF-5
Consolidated Statements of Cash FlowsF-6
Notes to Consolidated Financial StatementsF-7
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.